Robert C. Lindsley

Oncology

450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 107 publications

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS).

Journal: American journal of hematology

Published: June 25, 2026

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2026

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Journal: Transplantation and cellular therapy

Published: April 28, 2026

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing.

Journal: Haematologica

Published: February 12, 2026

MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy.

MEDUSA: Maintaining Entire DNA Duplexes for Utmost Sequencing Accuracy.

Journal: Clinical chemistry

Published: February 09, 2026

Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease.

Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease.

Journal: Blood

Published: February 05, 2026

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Journal: Blood

Published: January 08, 2026

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

Journal: American journal of hematology

Published: December 15, 2025

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Journal: Blood advances

Published: December 11, 2025

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial.

Journal: Blood advances

Published: December 11, 2025

Exposure to Agent Orange and Association with Myelodysplastic Syndromes.

Exposure to Agent Orange and Association with Myelodysplastic Syndromes.

Journal: Blood advances

Published: December 01, 2025

Exposure to Agent Orange and association with myelodysplastic syndromes.

Exposure to Agent Orange and association with myelodysplastic syndromes.

Journal: Blood advances

Published: December 01, 2025

Showing 1-12 of 107

Last Updated: 09/26/2026